Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone
Brief Summary: The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.


Options:
A: Arm Label: Abatacept + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Arm Label: Placebo + Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Arm Label: Abatacept + Methotrexate Open Label; Type: EXPERIMENTAL; Interventions: Drug: Abatacept, Drug: Methotrexate | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Abatacept + Methotrexate, Abatacept + Methotrexate Open Label, Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate
B: Arm Label: CP 690,550 1 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 15 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 3 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP 690,550 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: CP-690,550 20 mg QD; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 1 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 15 mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 3 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP 690,550 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): CP-690,550 20 mg QD | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate placebo | Arm Label: Adalimumab + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab, Drug: Methotrexate | Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Biological: Adalimumab placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab, Adalimumab + methotrexate | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Adalimumab + methotrexate, Methotrexate | Intervention Type: BIOLOGICAL; Name: Adalimumab placebo; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Methotrexate placebo; Assigned to Arm(s): Adalimumab

Answer: B